Ge Long Hui·2025-10-27 03:57Core Insights - UBS report indicates WuXi AppTec's Q3 revenue increased by 15% year-on-year to 12.1 billion yuan, surpassing both UBS and market estimates of 11.4 billion yuan and 11.5 billion yuan respectively [1] - Net profit rose by 53% year-on-year to 3.5 billion yuan, exceeding UBS and market forecasts of 3.3 billion yuan and 3.1 billion yuan [1] - As of the end of Q3, the company's backlog of ongoing orders increased by 41% year-on-year to 59.9 billion yuan [1] Business Developments - The company announced the divestiture of its clinical contract research organization/site management organization business, with an initial transaction price of 2.8 billion yuan [1] - UBS views this sale as beneficial for WuXi AppTec, allowing the company to focus on its core contract research, development, and manufacturing organization business and its global expansion [1] Financial Forecasts - UBS raised its earnings per share forecast for the company by 23.4% for this year, with 2024 to 2028 earnings estimates adjusted upward by 0.3% to 0.9% [1] - The target price for the company was increased from 136.1 HKD to 138.4 HKD, maintaining a "Buy" rating [1]